Key Points
- CEO Nikhil Lalwani sold 5,400 ANI Pharmaceuticals shares at an average price of $71, generating $383,400. The transaction was conducted under a pre-arranged Rule 10b5-1 plan and reduced his holdings by 1.57% to 339,089 shares.
- ANI Pharmaceuticals reported stronger-than-expected quarterly results, with EPS of $2.21 versus the $2.04 consensus and revenue of $266.04 million, up 25.8% year over year.
- Analyst sentiment remains generally positive, with a consensus “Moderate Buy” rating and an average price target of $103, although several firms recently lowered ratings or price targets.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Get Free Report) CEO Nikhil Lalwani sold 5,400 shares of the company's stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $71.00, for a total value of $383,400.00. Following the sale, the chief executive officer owned 339,089 shares of the company's stock, valued at $24,075,319. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Nikhil Lalwani also recently made the following trade(s):
- On Tuesday, August 25th, Nikhil Lalwani sold 5,400 shares of ANI Pharmaceuticals stock. The shares were sold at an average price of $74.30, for a total transaction of $401,220.00.
ANI Pharmaceuticals Stock Performance
Shares of ANIP opened at $73.59 on Thursday. The company has a debt-to-equity ratio of 0.99, a quick ratio of 2.41 and a current ratio of 2.91. The stock has a market capitalization of $1.69 billion, a P/E ratio of 15.86 and a beta of 0.45. The company's fifty day moving average is $76.47 and its two-hundred day moving average is $78.11. ANI Pharmaceuticals, Inc. has a 1 year low of $69.58 and a 1 year high of $98.55.
ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last released its earnings results on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, topping the consensus estimate of $2.04 by $0.17. The company had revenue of $266.04 million during the quarter, compared to analysts' expectations of $260.13 million. ANI Pharmaceuticals had a net margin of 11.07% and a return on equity of 27.37%. The business's revenue was up 25.8% on a year-over-year basis. During the same quarter last year, the business earned $1.80 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current year.
Wall Street Analyst Weigh In
A number of equities research analysts recently commented on the stock. Wall Street Zen downgraded shares of ANI Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 8th. Guggenheim dropped their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a "buy" rating on the stock in a research report on Monday, August 10th. Weiss Ratings downgraded ANI Pharmaceuticals from a "buy (b-)" rating to a "hold (c+)" rating in a research note on Tuesday, August 11th. Canaccord Genuity Group reduced their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a "hold" rating for the company in a report on Monday, August 10th. Finally, Leerink Partners initiated coverage on ANI Pharmaceuticals in a research note on Wednesday, September 9th. They issued an "outperform" rating and a $104.00 price target on the stock. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $103.00.
Read Our Latest Research Report on ANIP
Institutional Trading of ANI Pharmaceuticals
Several hedge funds and other institutional investors have recently made changes to their positions in the stock. Arrowstreet Capital Limited Partnership boosted its holdings in ANI Pharmaceuticals by 19.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 564,360 shares of the specialty pharmaceutical company's stock worth $43,399,000 after buying an additional 91,153 shares in the last quarter. Dimensional Fund Advisors LP increased its holdings in ANI Pharmaceuticals by 8.9% in the first quarter. Dimensional Fund Advisors LP now owns 531,190 shares of the specialty pharmaceutical company's stock valued at $40,843,000 after buying an additional 43,523 shares in the last quarter. Ranger Investment Management L.P. acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at approximately $28,406,000. Deutsche Bank AG acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter valued at approximately $26,775,000. Finally, William Blair Investment Management LLC purchased a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth approximately $21,372,000. Institutional investors and hedge funds own 76.05% of the company's stock.
ANI Pharmaceuticals Company Profile
(
Get Free Report)
ANI Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and markets branded and generic prescription medicines. The company focuses on products with complex formulations, manufacturing requirements or specialized commercial opportunities, and serves a range of therapeutic areas.
ANI's portfolio includes Cortrophin-Zinc, a repository corticotropin injection used for certain autoimmune and inflammatory conditions, along with a selection of branded and generic medicines.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
